... Morgan Stanley's "research analyst" David Risinger, who today, February 18, 2014, a day after the WSJ broke the news yesterday around 10:30 pm [2]that Forest Labs would be acquired by Actavis for $25 billion, decided to upgrade FRX from Equal-Weight to Overweight, and boosted his price target from "NA" to $86 or about where the stock was trading first thing this morning after the WSJ news. And that, ladies and gentlemen, is undisputed sell-side research value added.
[3]
And... Penguins.
[4]